Glargine plus Lixisenatide or vildagliptin succeeding to BOT T2DM control evaluation trial in Kobe

Trial Profile

Glargine plus Lixisenatide or vildagliptin succeeding to BOT T2DM control evaluation trial in Kobe

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Lixisenatide (Primary) ; Vildagliptin (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms GLP-ONE-KOBE
  • Most Recent Events

    • 21 May 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 03 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top